Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 1
2011 1
2012 1
2014 1
2023 0
Text availability
Article attribute
Article type
Publication date

Search Results

4 results
Results by year
Filters applied: . Clear all
Page 1
A humanized anti-IL-6 antibody (ALD518) in non-small cell lung cancer.
Bayliss TJ, Smith JT, Schuster M, Dragnev KH, Rigas JR. Bayliss TJ, et al. Expert Opin Biol Ther. 2011 Dec;11(12):1663-8. doi: 10.1517/14712598.2011.627850. Epub 2011 Oct 13. Expert Opin Biol Ther. 2011. PMID: 21995322 Review.
Preclinical and Phase I and II studies of ALD518 with a focus on NSCLC. How ALD518 could be used in NSCLC in the future. EXPERT OPINION: IL-6-mediated inflammation may contribute to NSCLC-related morbidity and mortality. In preclinical and Phase I and II trials A
Preclinical and Phase I and II studies of ALD518 with a focus on NSCLC. How ALD518 could be used in NSCLC in the future. EXPER …
Novel investigational biologics for the treatment of cancer cachexia.
Ma JD, Heavey SF, Revta C, Roeland EJ. Ma JD, et al. Expert Opin Biol Ther. 2014 Aug;14(8):1113-20. doi: 10.1517/14712598.2014.907788. Epub 2014 Apr 7. Expert Opin Biol Ther. 2014. PMID: 24707881 Review.
Several investigational biologics targeting key inflammatory pathways and/or the myostatin/activin type II receptor pathway are in development. AREAS COVERED: Novel therapies include ALD518, MABp1, IP-1510, OHR/AVR118, bimagrumab and REGN1033 and are discussed. ...
Several investigational biologics targeting key inflammatory pathways and/or the myostatin/activin type II receptor pathway are in developme …
A phase II, double-blind, randomised, placebo-controlled study of BMS945429 (ALD518) in patients with rheumatoid arthritis with an inadequate response to methotrexate.
Mease P, Strand V, Shalamberidze L, Dimic A, Raskina T, Xu LA, Liu Y, Smith J. Mease P, et al. Ann Rheum Dis. 2012 Jul;71(7):1183-9. doi: 10.1136/annrheumdis-2011-200704. Epub 2012 Feb 10. Ann Rheum Dis. 2012. PMID: 22328739 Clinical Trial.
BACKGROUND: Interleukin 6 (IL-6) plays a key role in the inflammatory cascade in rheumatoid arthritis. BMS945429 is a humanised, monoclonal antibody that potently binds IL-6. OBJECTIVE: To conduct aphase II study to determine the efficacy and safety of BMS945429 in …
BACKGROUND: Interleukin 6 (IL-6) plays a key role in the inflammatory cascade in rheumatoid arthritis. BMS945429 is a humanised, monoclon